These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31555219)

  • 1. Gut Dysfunction and Non-alcoholic Fatty Liver Disease.
    Grabherr F; Grander C; Effenberger M; Adolph TE; Tilg H
    Front Endocrinol (Lausanne); 2019; 10():611. PubMed ID: 31555219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver and the gut microbiota.
    Bashiardes S; Shapiro H; Rozin S; Shibolet O; Elinav E
    Mol Metab; 2016 Sep; 5(9):782-94. PubMed ID: 27617201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease.
    Zhou J; Tripathi M; Sinha RA; Singh BK; Yen PM
    Hepatoma Res; 2021; 7():11. PubMed ID: 33490737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
    Han R; Ma J; Li H
    Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Buffet C
    Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage.
    Neuman MG; French SW; Zakhari S; Malnick S; Seitz HK; Cohen LB; Salaspuro M; Voinea-Griffin A; Barasch A; Kirpich IA; Thomes PG; Schrum LW; Donohue TM; Kharbanda KK; Cruz M; Opris M
    Exp Mol Pathol; 2017 Feb; 102(1):162-180. PubMed ID: 28077318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
    Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
    Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic steatohepatitis: a microbiota-driven disease.
    Moschen AR; Kaser S; Tilg H
    Trends Endocrinol Metab; 2013 Nov; 24(11):537-45. PubMed ID: 23827477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
    Wree A; Geisler LJ; Tacke F
    Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.